

# Simplifying the complex.

ZEISS Glaucoma Workplace



// INNOVATION  
MADE BY ZEISS

CE 0297

Glaucoma Workplace  
FORUM

Carl Zeiss Meditec, Inc.  
5160 Hacienda Drive  
Dublin, CA 94568  
USA  
[www.zeiss.com/med](http://www.zeiss.com/med)  
[www.zeiss.com/med/contacts](http://www.zeiss.com/med/contacts)

 Carl Zeiss Meditec AG  
Goeschwitzer Strasse 51 – 52  
07745 Jena  
GERMANY  
[www.zeiss.com/med](http://www.zeiss.com/med)

**GWP9435** Printed in the United States. CZ-XI/2017 United States Edition: Only for sale in selected countries. The contents of the brochure may differ from the current status of approval of the product or service offering in your country. Please contact our regional representative for more information. Subject to changes in design and scope of delivery and as a result of ongoing technical development. CIRRU, Humphrey, HFA, Guided Progression Analysis and GPA are either trademarks or registered trademarks of Carl Zeiss Meditec AG or other companies of the ZEISS Group in Germany and/or other countries. © Carl Zeiss Meditec Inc., 2017. All copyrights reserved.



**Glaucoma Workplace from ZEISS**

Streamline your decision-making




## Information delivery at a glance.

Side-by-side progression data from CIRRUS HD-OCT and Humphrey Field Analyzer.

Glaucoma is a complex disease of progression. ZEISS Glaucoma Workplace empowers you to see glaucoma in a new way. Streamlining diagnosis to management, Glaucoma Workplace delivers progression data you need to help you identify and manage glaucoma patients like never before.

Integrating individual data sets into a single visualization helps to guide your assessments by spotlighting changes that can impact disease management.

- 1 Monitor your patient's treatment:**  
Trend Analysis for both structure and function shows progression over time
- 2 Progression status guidance:**  
GPA alert is a plain language message "Possible Progression" or "Likely Progression"
- 3 Easily identify change:**  
Color-coded alerts help you quickly identify statistically significant change




The above example illustrates damage that is affecting the eye's function (HFA) and structure (OCT) concurrently. Both show typical glaucomatous damage expanding in the superior nasal hemifield, (reflected in the inferior hemifield on the OCT). The trend analyses for both structure and function show continuous progression; an indicator that treatment for this patient may need adjustment to minimize further loss.

## Know sooner than later.

Identify with clarity. Respond with confidence.

Preserving vision requires making the right decisions at the right time; making those decisions with confidence starts with detecting change as early as possible.




In the above example of pre-perimetric glaucomatous damage:

- 1. Identify downward trending:** Loss of average RNFL thickness is an important indicator
- 2. Compare to other data:** Trend line for the HFA visual field index is flat, even though OCT progression map shows visible damage as early as 2012/2013
- 3. RNFL loss in 2013:** RNFL loss detected before visual field loss
- 4. Evaluate Visual Field Loss in 2016:** Visual field loss detected 3 years after pre-perimetric loss was first found\*



- **Mark Important Clinical Events (1):** Indicate timing of intervention and initiation of new trend analysis
- **Customize GPA parameters:** As status changes, create dual baselines (2&3) to display rates of progression before and after intervention



Structure + Function

### ASSESS EARLY

Observe structural and functional changes early with CIRRUS™ HD-OCT and Humphrey® Field Analyzer

### IDENTIFY CHANGE

Visualize statistically significant change and progression over time Structure-Function Guided Progression Analysis™ (GPA™)

### INDIVIDUALIZE THERAPY

Respond early to changes in disease status

### VIEW INTEGRATED INFORMATION

Evaluate information efficiently displayed in simple side-by-side format

*"There are multiple challenges for the doctor managing glaucoma: first, is to accurately diagnose and stage glaucoma; and second, to quickly identify progression in those patients where therapy has been insufficient."*

— Nathan Radcliffe, MD